Abstract
Dual antiplatelet therapy (aspirin plus clopidogrel) is mandatory in patients treated with coronary stent implantation. This strategy is highly effective in prevention of stent thrombosis until its struts are covered with endothelium. However, a substantial number of patients still suffer from recurrent ischemic coronary events despite adequate antiplatelet therapy. These events fall into three categories: stent thrombosis, in stent restenosis and events related to other nonstented coronary lesions. Some data suggest that beside other local and systemic factors resistance to aspirin and clopidogrel may be a possible cause of stent thrombosis and ischemic events in patients after coronary interventions. Several mechanisms of antiplatelet drug resistance have been reported including poor compliance, interactions with other drugs, genetic polymorphism or increased platelet turnover. More research is needed to adequately assess the clinical significance and prognostic value of antiplatelet drug resistance detected by laboratory tests in patients undergoing percutaneous intervention. We review published data on mechanisms and the clinical significance of aspirin and clopidogrel resistance in patients after coronary interventions.
Keywords: Aspirin and clopidogrel resistance, percutaneous coronary interventions
Current Vascular Pharmacology
Title: Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions
Volume: 5 Issue: 2
Author(s): Jerzy Pregowski, Adam Witkowski and Dariusz Sitkiewicz
Affiliation:
Keywords: Aspirin and clopidogrel resistance, percutaneous coronary interventions
Abstract: Dual antiplatelet therapy (aspirin plus clopidogrel) is mandatory in patients treated with coronary stent implantation. This strategy is highly effective in prevention of stent thrombosis until its struts are covered with endothelium. However, a substantial number of patients still suffer from recurrent ischemic coronary events despite adequate antiplatelet therapy. These events fall into three categories: stent thrombosis, in stent restenosis and events related to other nonstented coronary lesions. Some data suggest that beside other local and systemic factors resistance to aspirin and clopidogrel may be a possible cause of stent thrombosis and ischemic events in patients after coronary interventions. Several mechanisms of antiplatelet drug resistance have been reported including poor compliance, interactions with other drugs, genetic polymorphism or increased platelet turnover. More research is needed to adequately assess the clinical significance and prognostic value of antiplatelet drug resistance detected by laboratory tests in patients undergoing percutaneous intervention. We review published data on mechanisms and the clinical significance of aspirin and clopidogrel resistance in patients after coronary interventions.
Export Options
About this article
Cite this article as:
Pregowski Jerzy, Witkowski Adam and Sitkiewicz Dariusz, Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions, Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368262
DOI https://dx.doi.org/10.2174/157016107780368262 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Metabolomics Reveals Hippurate as a Urinary Potential Marker for Diabetic Nephropathy
Current Metabolomics Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes
Current Pharmaceutical Design Synthesis and Investigating Hypoglycemic and Hypolipidemic Activities of Some Glibenclamide Analogues in Rats
Mini-Reviews in Medicinal Chemistry Ligand-Based Pharmacophore Detection, Screening of Potential Gliptins and Docking Studies to Get Effective Antidiabetic Agents
Combinatorial Chemistry & High Throughput Screening Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Circadian Rhythm of Blood Pressure in Diabetes Mellitus: Evidence, Mechanisms and Implications
Current Diabetes Reviews Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives
Current Medicinal Chemistry 3,4,5-Trihydroxybenzoic Acid Attenuates Ligature-Induced Periodontal Disease in Wistar Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Derivatives of 6-Nitrobenzimidazole Inhibit Fructose-Mediated Protein Glycation and Intracellular Reactive Oxygen Species Production
Medicinal Chemistry Adipose Tissue Macrophages, Low Grade Inflammation and Insulin Resistance in Human Obesity
Current Pharmaceutical Design Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiobesity Carbonic Anhydrase Inhibitors
Current Topics in Medicinal Chemistry The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Editorial [Hot Topic: Plasminogen Activator Inhibitor-1 (Guest Editor: Daniel A. Lawrence)]
Current Drug Targets Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets